OVERVIEW OF CURRENT DEVELOPMENTS IN MEASURING AND REPORTING PATIENT REPORTED OUTCOMES AND QUALITY OF LIFE IN GYNAECOLOGICAL CANCER

ESGO eAcademy, Lonneke van de Poll-Franse, 202809

CERVICAL CANCER IMMUNOTHERAPY TRIAL

ESGO eAcademy, Hans W. Nijman, 202804

MANAGEMENT OF RECURRENT DISEASE

ESGO eAcademy, Frederic Amant, 202799

OVARIAN CANCER IMMUNOTHERAPY TRIALS

ESGO eAcademy, Jonathan Ledermann, 202803

CONSERVATIVE TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN

ESGO eAcademy, Dimitrios Haidopoulos, 202798

RADICAL TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN

ESGO eAcademy, Nicoletta Colombo, 202797

PRINCIPLES OF IMMUNOTHERAPY

ESGO eAcademy, Christian Marth, 202801

RISK FACTORS AND PATHOGENESIS OF ENDOMETRIAL CANCER IN YOUNG WOMEN

ESGO eAcademy, Vesna I. Kesic, 202796

Prognostic Value Of Lymph Node Ratio And Number Of Positive Inguinal Nodes In Patients With Vulvar Cancer

ESGO eAcademy, Richard Schwameis, 202924

ONCOLOGICAL MANAGEMENT AND PREGNANCY OUTCOMES IN WOMEN DIAGNOSED WITH CANCER DURING PREGNANCY: A 20-YEAR INTERNATIONAL COHORT STUDY OF 1170 PATIENTS

ESGO eAcademy, Frederic Amant, 202790

MECHANISMS OF RESISTANCE IN BRCA MUTATED TUMORS

ESGO eAcademy, Clare Scott, 202793

QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY

ESGO eAcademy, Sarah Blagden, 202788

CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)

ESGO eAcademy, Gourley Charlie, 202787

CLINICAL DEVELOPMENT OF OTHER NON PARP TARGETED THERAPIES

ESGO eAcademy, Cristiana Sessa, 202792

HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) FOR OVARIAN CANCER

ESGO eAcademy, Willemien Van Driel, 202786

UPDATE ON THE CLINICAL DEVELOPMENT OF PARP INHIBITORS

ESGO eAcademy, Iain McNeish, 202791

ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC)

ESGO eAcademy, Jonathan Ledermann, 202785

Vulvar Cancer In Ireland: Analysis Of The Irish National Cancer Registry Over A 20 Year Period

ESGO eAcademy, Ann Rowan, 203117

STRATEGIES FOR OVERCOMING RESISTANCE TO CHEMOTHERAPY

ESGO eAcademy, Sandro Pignata, 202780

PLATINUM-RESISTANT DISEASE: CURRENT STATUS

ESGO eAcademy, Nicole Concin, 202779

RANKL -BONES, SEX, AND BREAST CANCER

ESGO eAcademy, Josef Penninger, 202794

WHY ARE WE FAILING TO CURE OVARIAN CANCER?"

ESGO eAcademy, Christian Marth, 202795

WHEN, WHY AND HOW TO TEST MISMATCH REPAIR DEFICIENCY IN ENDOMETRIAL CANCER

ESGO eAcademy, Tjalling Bosse, 202778

GENERAL IMPLEMENTATION OF IGABT (TRAINING/ MEANS/HEALTH ECONOMICS/RESOURCE LIMITATIONS)

ESGO eAcademy, Christine Haie-Meder, 202775

WHEN, WHY AND HOW TO TEST FOR L1CAM AND P53 EXPRESSION IN ENDOMETRIAL CANCER

ESGO eAcademy, Alain Zeimet, 202777

IMAGE-GUIDED ADAPTIVE BRACHYTHERAPY VERSUS IMRT/STEREOTACTIC RADIOTHERAPY

ESGO eAcademy, Akila Viswanathan, 202774

CURRENT STATUS OF IMAGE-GUIDED BRACHYTHERAPY : ONCOLOGICAL RESULTS AND COMPLICATIONS

ESGO eAcademy, Jacob Lindegaard, 202773

WHEN, WHY AND HOW TO TEST POLE MUTATIONAL STATUS IN ENDOMETRIAL CANCER

ESGO eAcademy, David Church, 202776

Interval Between  Cytoreductive Surgery And Adjuvant Chemotherapy Is Associated With Overall Survival In  Patients With Advanced Ovarian Cancer

ESGO eAcademy, Maite Timmermans, 202923

Outcomes Of Robotic Radical Hysterectomy For Cervical Cancer In Comparison To Laparotomy ; A Population Based Study In The United States

ESGO eAcademy, Sabrina Piedimonte, 202922

TREATMENT OF ADVANCED DISEASE, INCLUDING MANAGEMENT OF MORBIDITY

ESGO eAcademy, Alexandra Taylor, 202769

IMPACT OF VAGINAL MORBIDITY ON SEXUALITY AFTER DEFINITIVE RADIOCHEMOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER PATIENTS

ESGO eAcademy, Kathrin Kirchheiner, 202772

ADJUVANT TREATMENT

ESGO eAcademy, Carien Creutzberg, 202768

PHYSICAL CONSEQUENCES OF GYNAECOLOGIC CANCER SURGERY AND THEIR IMPACT ON SEXUAL HEALTH

ESGO eAcademy, Michal Zikan, 202771

Cervical Cancer Relapse Rates In Patients With Para-Aortic Negitive PET Scans:A Five-Year Analysis In An Irish Gynaeoncology Centre

ESGO eAcademy, Ann Rowan, 202921

DIAGNOSTIC AND SURGICAL MANAGEMENT

ESGO eAcademy, Philippe Morice, 202767

SEXUAL HEALTH IN GYNAECOLOGIC CANCER PATIENTS - PSYCHO-SOCIAL CONSEQUENCES OF DIAGNOSIS AND TREATMENT

ESGO eAcademy, Moniek M ter Kuile, 202770

Patterns Of Lymph Node Metastases In Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study.

ESGO eAcademy, Lucas Minig, 202920

Long-Term Efficacy And Immunogenicity Of The 9-Valent Human Papillomavirus Vaccine: Final Analyses Of A Double-Blind, Randomized Clinical Study

ESGO eAcademy, Elmar Joura, 202919

REAL-TIME FLUORESCENCE GUIDED-SURGERY WITH ICG FOR SENTINEL LYMPH NODE (SLN) MAPPING IN CASE OF EARLY STAGE CERVICAL OR ENDOMETRIAL CANCER

ESGO eAcademy, Alessandro Buda, 234282

Mucinous Ovarian Cancer (MOC): What Is The Reproducibility Of The WHO Classification?

ESGO eAcademy, Mojgan Devouassoux, 202918

Refinement Of High-Risk Endometrial-Cancer (HR-EC) Classification Using DNA Damage Response (DDR) Biomarkers: A Transportec Initiative

ESGO eAcademy, Aurélie AUGUSTE, 202917

PERIOPERATIVE CARE OF THE ELDERLY PATIENT

ESGO eAcademy, Karl Tamussino, 202765

Adverse Events After Hyperthermic Intraperitoneal Chemotherapy (HIPEC) For Stage III Ovarian Cancer: Phase III OVHIPEC Study

ESGO eAcademy, Simone Koole, 202916

MANAGEMENT OF ADVANCED STAGES AND RECURRENT DISEASE

ESGO eAcademy, Richard Poetter, 202761

MANAGEMENT OF EARLY STAGES

ESGO eAcademy, David Cibula, 202760

Perioperative Positioning Management In Gynecologic Cancer Surgery: A National NOGGO-AGO Intergroup Survey

ESGO eAcademy, Jenny Katharina Wagner, 202915

WHAT´S NEW IN ANESTHESIA FOR HIGH-RISK PATIENTS: WHAT SURGEONS NEED TO KNOW

ESGO eAcademy, Stephanie Suria, 202763

PATHOLOGY REPORT   

ESGO eAcademy, Maria Rosaria Raspollini, 202759

SHAPING NEW CLINICAL PRACTICE GUIDELINES

ESGO eAcademy, David Cibula, 202758

INITIATING ENHANCED RECOVERY: CHALLENGES AND OPPORTUNITIES

ESGO eAcademy, Lena Wijk, 202762

Hormonal And Fertility Outcome After Fertility Sparing Surgery And Chemotherapy For Ovarian Neoplasms: A Retrospective Study

ESGO eAcademy, Lorenzo Ceppi, 202914

MRI-Based Predictive Factors Of Axillary Lymph Node Metastases In Breast Cancer

ESGO eAcademy, David Atallah, 202913

Experience In Introducing Sentinel Lymph Node Biopsy In Early- Stage Vulva Cancer: A Single Institution Based Prospective Study

ESGO eAcademy, Frøding Ligita, 202912

ESGO – A STORY OF SUCCESS

ESGO eAcademy, David Cibula, 202757

INTRODUCTION

ESGO eAcademy, Luis Chiva, 202756

SUMMARY AND CONCLUSIONS

ESGO eAcademy, Gabriele Calaminus, 202755

CASE PRESENTATION 2 :SERTOLI LEYDIG CELL TUMOR

ESGO eAcademy, Cristiana Sessa, 202754

TREATMENT OF RECURRENT AND METASTATIC DISEASE

ESGO eAcademy, Ate Van Der Zee, 202749

CASE PRESENTATION 2 :SERTOLI LEYDIG CELL TUMOR

ESGO eAcademy, Dominik Schneider, 202753

CASE PRESENTATION 1 :STAGE I GRADE 3 IMMATURE TERATOMA

ESGO eAcademy, Philippe Morice, 202752

CASE PRESENTATION 1 :STAGE I GRADE 3 IMMATURE TERATOMA

ESGO eAcademy, Gabriele Calaminus, 202751

DIAGNOSIS, STAGING AND PREOPERATIVE WORKUP

ESGO eAcademy, Maaike Oonk, 202747

Pathological aspects of uterine carcinocarcoma

ESGO eAcademy, Mojgan Devouassoux, 202903

ROBOTIC EXPERT VIDEO

ESGO eAcademy, Rainer Kimmig, 261658

CIRCULATING TUMOR CELLS: CHALLENGES & PERSPECTIVES IN GYNAECOLOGICAL CANCERS

ESGO eAcademy, Catherine Alix-Panabieres, 202731

QUESTIONS REMAINED TO BE ANSWERED

ESGO eAcademy, David Cibula, 202728

DETECTION OF METHYLATED DNA IN VARIOUS BODY FLUIDS AND THEIR USE AS DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE TOOLS IN GYNAECOLOGICAL CANCERS

ESGO eAcademy, Heidi Fiegl, 202730

SLN IMPLEMENTATION INTO MANAGEMENT ALGORITHMS

ESGO eAcademy, Nadeem R. Abu-Rustum, 202727

WHOLE-GENOME SEQUENCING OF CELL-FREE DNA IN GYNAECOLOGICAL CANCERS

ESGO eAcademy, Adriaan Vanderstichele, 202729

DEVELOPMENTS IN DETECTION TECHNIQUES

ESGO eAcademy, Eric Leblanc, 202726

Ultrasound Characteristics Of Endometrial Cancer As Defined By The International Endometrial Tumor Analysis (IETA) Consensus Nomenclature- A Prospective Multicenter Study

ESGO eAcademy, Daniela Fischerova, 202910

UTERINE CORPUS

ESGO eAcademy, Sigurd Lax, 202725

WHAT MODIFIES THE OUTCOME OF RECURRENT GRANULOSA CELL TUMORS OF THE OVARY?

ESGO eAcademy, Isabel Carriles, 202721

OVARY AND FALLOPIAN TUBE

ESGO eAcademy, Xavier Matias-Guiu, 202724

PRE-SURGICAL METFORMIN IN UTERINE MALIGNANCY-RESULTS OF THE PREMIUM RANDOMISED CONTROLLED TRIAL

ESGO eAcademy, Sarah Kitson, 202719

Development And Pre-Testing Of The Eortc Quality Of Life Questionnaire For Vulva Cancer Patients – The Significance Of Patient Involvement

ESGO eAcademy, Pernille Jensen, 202909

CERVIX, VULVA, VAGINA

ESGO eAcademy, Glenn McCluggage, 202723

Prognostic Factors For Local Recurrence Of Squamous Cell Carcinoma Of The Vulva: A Systematic Review

ESGO eAcademy, Nienke Te Grootenhuis, 202908

The New Normal; Sexual Function after Ovarian Cancer for Survivors and Partners Compared to Normdata

ESGO eAcademy, Maria Caroline Vos, 202907

VULVA CANCER

ESGO eAcademy, Ate Van Der Zee, 202709

The Role Of The Peritoneal Cancer Index In Surgery For Advanced Ovarian Cancer

ESGO eAcademy, Mikkel Rosendahl, 202906

HOW LONG SHOULD HORMONAL TREATMENT BE CONTINUED BEFORE DECIDING FOR HYSTERECTOMY IN THE FERTILITY SPARING MANAGEMENT OF ENDOMETRIAL CANCER?

ESGO eAcademy, Nicoletta Colombo, 202704

OVARIAN CANCER

ESGO eAcademy, Christoph Grimm, 202708

FERTILITY SPARING MANAGEMENT IN CERVICAL CANCERS BETWEEN 2 AND 4 CM: RADICAL TRACHELECTOMY BY LAPAROTOMY OR NEO-ADJUVANT CHEMOTHERAPY?

ESGO eAcademy, Ignace Vergote, 202703

The Peritoneal Cancer Index(PCI): Selted Regions - And Not The Total PCI - Are Predictive Of Survival In Advanced Ovarian Cancer

ESGO eAcademy, Mikkel Rosendahl, 202905

CERVICAL CANCER

ESGO eAcademy, Daniela Fischerova, 202707

CAN WE SAFELY USE OVARIAN HYPERSTIMULATION IN INFERTILE PATIENTS AFTER FSS FOR EPITHELIAL TUMORS?

ESGO eAcademy, Dominik Denschlag, 202702

Imaging in the diagnosis and management of endometrial cancer

ESGO eAcademy, Ingfrid Haldorsen, 202706

FERTILITY SPARING MANAGEMENT IN HIGH RISK EPITHELIAL OVARIAN CANCER

ESGO eAcademy, Enrica Bentivegna, 202701

CHANGES IN NEOANGIOGENETIC PROFILE OF PAIRED PRIMARY AND RECURRENT HIGH-GRADE SEROUS OVARIAN CANCER (HGOSC): A STUDY OF THE “OCTIPS” CONSORTIUM.

ESGO eAcademy, Ilary Ruscito, 202699

CISPLATIN CHEMO-RADIATION VERSUS RADIATION IN FIGO STAGE IIIB SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX (CRACX TRIAL: NCT00193791)

ESGO eAcademy, Umesh Mahantshetty, 202698

EMBRACE THE MOLECULAR CLASSIFICATION OF ENDOMETRIAL CANCER

ESGO eAcademy, Tjalling Bosse, 202696

Randomized Controlled Phase III Study To Evaluate Secondary Cytoreductive Surgery In Platinum-Sensitive Recurrent Ovarian Cancer - AGO Desktop III/ENGOT Ov20

ESGO eAcademy, Jalid Sehouli, 202904

Medical treatment of uterine carcinosarcoma

ESGO eAcademy, Isabelle Ray-Coquard, 190586

Surgical treatment of serous endometrial cancer

ESGO eAcademy, Frederic Guyon, 190585

Long- term therapy with gonadoliberin analogues in patient with ovarian cancer.

ESGO eAcademy, Faculty / Presenters, 191006

High grade serous ovarian cancer stage IV, multiple relapses

ESGO eAcademy, Faculty / Presenters, 191003

Ovarian Cancer in Pregnancy

ESGO eAcademy, Faculty / Presenters, 190595

Surgical treatment of low grade serous ovarian cancer

ESGO eAcademy, Jalid Sehouli, 180471